DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Leukeran (Chlorambucil) - Published Studies


Leukeran Related Published Studies

Well-designed clinical trials related to Leukeran (Chlorambucil)

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. [2009.09.10]

Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome. [2009.09]

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. [2007.12.10]

The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. [2006.11]

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. [2006.09.01]

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). [2005.10]

Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. [2005.03]

Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia. [2004.10]

Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. [2004.01]

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. [2001.08.15]

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. [2000.12.14]

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. [2000.10.15]

Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. [2000.03]

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. [1998.05.21]

Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. [1998.05]

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. [1998.03]

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. [1997.07]

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. [1997.06.01]

Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis. [1997.06]

A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. [1995.11]

Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. [1995.09]

Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. [1994.09.01]

A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. [1994]

Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. [1994]

The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. [1993.11]

Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. [1992.12]

Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. [1992.08.27]

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. [1992.02]

Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. [1992.01]

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. [1991.05]

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. [1991.04]

Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group. [1991]

A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. [1991]

Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. [1991]

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. [1989.05]

A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. [1989.03]

A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. [1989.01.05]

Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. [1988.02.01]

Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. [1988.01]

Inter- and intraindividual differences in oral chlorambucil pharmacokinetics. [1988]

High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCI CLL-01 trial. [1988]

CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study. [1988]

A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. [1988]

Well-designed clinical trials possibly related to Leukeran (Chlorambucil)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. [2011.06.01]

An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. [2010.06]

A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. [2006.02]

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). [2005.12.20]

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. [2004.02]

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. [2003.08.16]

Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. [2003.04.15]

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. [2002.07.01]

Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. [2002.02]

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. [2001.07.06]

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. [2001.05.18]

Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. [2001.05]

Paraproteinemic Neuropathy. [2001.03]

Treatment of membranous nephropathy. [2001]

Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. [1999.02]

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. [1998.05]

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. [1998.01]

UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain. [1997.09]

CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group. [1997.07]

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. [1997.03]

Cytotoxics, cyclosporine and membranous nephropathy. [1996.09]

[Verification of indications for kidney biopsy in children with steroid-dependent nephrotic syndrome] [1996.08]

Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. [1996.05]

The follicular non-Hodgkin's lymphomas--I. The possibility of cure. [1996.03]

ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. [1996]

Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. [1995.12]

Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. [1995.09]

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. [1995.09]

Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. [1995.02]

Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. [1995.01]

Pharmacokinetics of a more reliable Chloraminophene formulation. [1995]

Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group. [1994.09]

Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis. [1994.04]

Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. [1994]

Incidence, presenting features and prognosis of low-grade B-cell non-Hodgkin's lymphomas. Population-based data from a Danish lymphoma registry. [1993.12]

Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. [1993]

Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma. [1993]

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. [1992.08]

Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. [1992.06]

West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. [1992]

Swiss adjuvant trials in women with node-negative breast cancer. OSAKO. [1992]

Effect of cyclosporine A on the hearing loss in Behcet's disease. [1991.06]

[A randomized trial of PVB, VAB-6, BVP regimen versus PEB chemotherapy in patients with disseminated testicular tumors] [1991.06]

Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. [1991.02]

Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP. [1991.01]

Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity. [1991]

High-intensity therapy versus low-intensity therapy in advanced breast cancer patients. [1990.09]

A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. [1990.01]

Prognostic significance of glucocorticoid receptor determination in patients with chronic lymphocytic leukemia and immunocytoma--lack of a positive correlation between receptor levels and clinical responsiveness. [1990]

[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)] [1990]

West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary lymph nodes. [1989.12]

Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. [1989.10]

Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results. [1989.03]

Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer. [1989]

Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. [1989]

Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. [1988.09.10]

Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. [1988.06]

The role of surgical reexploration following chemotherapy in ovarian cancer. [1988.05]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017